Medi-Cal: reimbursement: blood factors.
Do you support it?
Want to know if it passes?
We'll email you when SB 525 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on SB 525.
You're tracking SB 525
We'll email you the moment it moves.
SB 525 — Medi-Cal: reimbursement: blood factors.
Last action — Returned to Secretary of Senate pursuant to Joint Rule 56.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
2In Committee
-
3Passed Senate
-
4Passed Assembly
-
5To Executive
-
6Enacted
This bill died with 2019-2020 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law provides for a schedule of benefits covered by the Medi-Cal program, including the purchase of prescribed drugs subject to the Medi-Cal list of contract drugs and utilization controls. Existing law authorizes the department to enter into contracts with manufacturers of drugs, to maintain a list of contract drugs, including blood factors, and to require pharmaceutical manufacturers to provide various rebates to the state. Existing law requires the reimbursement for blood factors to be by national drug code number and to not exceed 120% of the average sales price of the last quarter reported. This bill would instead require the reimbursement for blood factors to be the lower of the wholesale acquisition cost, 120% of the average sales price of the last quarter reported, or the actual acquisition cost for the drug plus a professional dispensing fee of $0.14 per unit. The bill would define those costs and fees for these purposes.
Bill Text
- Amended 04/11/19 - Amended Senate Current pdf April 11, 2019
- Amended 03/27/19 - Amended Senate pdf March 27, 2019
- Introduced 02/21/19 - Introduced pdf February 21, 2019
- SB525 View text html
Action History
-
Returned to Secretary of Senate pursuant to Joint Rule 56.
-
April 24 set for first hearing canceled at the request of author.
-
From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH.
-
Set for hearing April 24.
-
Re-referred to Com. on HEALTH.
-
From committee with author's amendments. Read second time and amended. Re-referred to Com. on RLS.
-
Referred to Com. on RLS.
-
From printer. May be acted upon on or after March 24.
-
Introduced. Read first time. To Com. on RLS. for assignment. To print.
Sponsors
- Mark Stone · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 121 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (121)
121 members have not signed on to this bill.
Show all 121 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does SB 525 do?
- Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Existing law provides for a schedule of benefits covered by the Medi-Cal program, including the purchase of prescribed drugs subject to the Medi-Cal list of contract drugs and utilization controls. Existing law authorizes the department to enter into contracts with manufacturers of drugs, to maintain a list of contract drugs, including blood factors, and to require pharmaceutical manufacturers to provide various rebates to the state. Existing law requires the reimbursement for blood factors to be by national drug code number and to not exceed 120% of the average sales price of the last quarter reported. This bill would instead require the reimbursement for blood factors to be the lower of the wholesale acquisition cost, 120% of the average sales price of the last quarter reported, or the actual acquisition cost for the drug plus a professional dispensing fee of $0.14 per unit. The bill would define those costs and fees for these purposes.
- Who sponsors SB 525?
- SB 525 is sponsored by Mark Stone.
- What is the current status of SB 525?
- This bill died with 2019-2020 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track SB 525?
- Track SB 525 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 525
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 525
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →